ProSpare improves anorectal dosimetry during postoperative prostate radiotherapy in the randomized POPS trial
ProSpare reduced anorectal dose and showed numerically lower grade ≥1 bowel symptoms, with its primary two-year outcome still pending.
ProSpare reduced anorectal dose and showed numerically lower grade ≥1 bowel symptoms, with its primary two-year outcome still pending.
In 77 high-risk prostate patients, five-fraction adaptive pelvic SBRT produced 6.9% late grade ≥2 GU and 9.7% GI toxicity.
ProSpare reduced anorectal dose and showed lower grade ≥1 bowel toxicity at 18 weeks, while the trial's primary two-year endpoint remains pending.
Five EORTC QLQ-PR25 scales now have proposed thresholds to identify clinically important urinary, bowel, hormonal and sexual problems in prostate cancer.
CycleGAN-generated needle-free ultrasound improved urethral contour agreement from 0.70 to 0.89 Dice after prostate HDR catheter insertion.
In 307 patients receiving EBRT and LDR brachytherapy boost, five-year biochemical control was 95%, with uncommon severe GU and GI toxicity.
Urinary microRNA profiles changed during prostate MR-SBRT and differed between patients with and without early grade ≥2 urinary toxicity.
MRI-linac R2* mapping detected transient prostate and tumour changes after two SABR fractions, supporting feasibility but not yet biomarker validity.
A 3D deep-learning nomogram predicted the clinical prescription isodose with high spatial agreement, adding geometry-aware verification to post-plan QA.
Relative oxygen extraction declined across irradiated prostate and tumor tissue during five-fraction MRgSBRT, with the largest early changes.
After prior TURP, focal SIB was not significantly associated with severe late GU toxicity, while repeated TURP consistently identified higher-risk patients.
Across 1,378 adaptive fractions, 4.6% had shifts above 6 mm and longer adaptation times were linked to greater prostate displacement.
In 22 patients, salvage HDR brachytherapy produced 40.5% five-year relapse-free survival but 18% developed grade ≥3 GU toxicity.
After neoadjuvant ADT, 40% of MRI-visible prostate lesions disappeared and remaining lesions shrank substantially more than the prostate gland.
Faster PSA rise after testosterone recovery tracked progression, but associations with distant metastasis were inconsistent and too imprecise for clinical inference.